Press Release
InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022
11 Apr, 2022
110
3727
InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China
30 Mar, 2022
91
3721
InnoCare to Hold 2022 R&D Day on April 20, 2022
29 Mar, 2022
111
3718
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
28 Mar, 2022
128
3703
InnoCare Releases 2021 Annual Results and Business Highlights
23 Mar, 2022
175
3688
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström’s Macroglobulinemia in China
14 Mar, 2022
119
3680
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022
11 Mar, 2022
77
3677
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
02 Mar, 2022
83
3671
InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP
22 Feb, 2022
115
3657
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
18 Jan, 2022
66
3650